Compare Sezzle Inc (SEZL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Sezzle Inc trades at $122.66 (market cap $4.39B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Sezzle Inc and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sezzle Inc for 15 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SEZL | TVTX | |
|---|---|---|
Market Cap | $4.39B | $4.88B |
Volume | 424,843 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $188.55 | $67.52 |
52-Week Low | $50.97 | $26.79 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $4.44B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sezzle (SEZL) trades at $130.05, down 0.33% today, with a bullish technical signal and strong support near $127. The company demonstrates robust fundamentals, with Q2 2026 revenue growth of 51.7% year-over-year and a net income margin of 30.35%. Recent product launches like Sezzle Send and SezzleCash are driving user growth, while analyst consensus remains positive with a $168 price target.
Outlook is favorable given sustained earnings beats and raised guidance, but risks include competitive pressures in the BNPL sector and elevated valuation multiples. The stock offers growth potential if execution continues, though overbought technical indicators suggest near-term volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
